AIM ImmunoTech Inc (AMEX: AIM) is -33.59% lower on its value in year-to-date trading and has touched a low of $0.11 and a high of $0.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AIM stock was last observed hovering at around $0.12 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.13, the stock is -3.87% and -26.46% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 6.56% at the moment leaves the stock -52.54% off its SMA200. AIM registered -67.17% loss for a year compared to 6-month loss of -61.70%.
The stock witnessed a -29.15% gain in the last 1 month and extending the period to 3 months gives it a -42.85%, and is -3.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.30% over the week and 15.31% over the month.
AIM ImmunoTech Inc (AIM) has around 26 employees, a market worth around $9.04M and $0.19M in sales. Profit margin for the company is -12594.21%. Distance from 52-week low is 19.00% and -78.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-686.04%).
The EPS is expected to grow by 50.00% this year
The shares outstanding are 68.75M, and float is at 60.91M with Short Float at 5.60%.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 4.08 million shares valued at $1.52 million. The investor’s holdings represent 7.718 of the AIM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.99 million shares valued at $0.74 million to account for 4.021 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 0.7 million shares representing 1.4118 and valued at over $0.26 million, while GEODE CAPITAL MANAGEMENT, LLC holds 0.759 of the shares totaling 0.4 million with a market value of $0.15 million.
AIM ImmunoTech Inc (AIM) Insider Activity
A total of 0 insider transactions have happened at AIM ImmunoTech Inc (AIM) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Equels Thomas K, the company’s CEO & President. SEC filings show that Equels Thomas K bought 44,000 shares of the company’s common stock on Mar 04 ’25 at a price of $0.12 per share for a total of $5060.0. Following the purchase, the insider now owns 1.81 million shares.
AIM ImmunoTech Inc disclosed in a document filed with the SEC on Mar 04 ’25 that Equels Thomas K (CEO & President) bought a total of 83,334 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $0.12 per share for $10000.0. Following the transaction, the insider now directly holds 1.76 million shares of the AIM stock.
Still, SEC filings show that on Nov 21 ’24, Equels Thomas K (CEO & President) acquired 20,000 shares at an average price of $0.21 for $4240.0. The insider now directly holds 1,657,968 shares of AIM ImmunoTech Inc (AIM).
